InterCure (INCR) Competitors $1.48 +0.01 (+0.68%) Closing price 07/1/2025 03:48 PM EasternExtended Trading$1.40 -0.08 (-5.07%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INCR vs. ADCT, TRDA, CRVS, ALLO, SGMT, TSVT, CDTX, FHTX, ANNX, and AMRNShould you be buying InterCure stock or one of its competitors? The main competitors of InterCure include ADC Therapeutics (ADCT), Entrada Therapeutics (TRDA), Corvus Pharmaceuticals (CRVS), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), 2seventy bio (TSVT), Cidara Therapeutics (CDTX), Foghorn Therapeutics (FHTX), Annexon (ANNX), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. InterCure vs. Its Competitors ADC Therapeutics Entrada Therapeutics Corvus Pharmaceuticals Allogene Therapeutics Sagimet Biosciences 2seventy bio Cidara Therapeutics Foghorn Therapeutics Annexon Amarin ADC Therapeutics (NYSE:ADCT) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Do analysts recommend ADCT or INCR? ADC Therapeutics currently has a consensus target price of $7.75, indicating a potential upside of 187.04%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe ADC Therapeutics is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ADCT or INCR more profitable? InterCure has a net margin of 0.00% compared to ADC Therapeutics' net margin of -197.64%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics-197.64% N/A -45.57% InterCure N/A N/A N/A Does the media refer more to ADCT or INCR? In the previous week, InterCure had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for InterCure and 2 mentions for ADC Therapeutics. InterCure's average media sentiment score of 0.62 beat ADC Therapeutics' score of 0.00 indicating that InterCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InterCure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, ADCT or INCR? InterCure has lower revenue, but higher earnings than ADC Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$70.84M3.78-$157.85M-$1.45-1.86InterCure$64.55M1.04-$18.32MN/AN/A Do institutionals and insiders have more ownership in ADCT or INCR? 41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, ADCT or INCR? ADC Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. SummaryADC Therapeutics beats InterCure on 8 of the 13 factors compared between the two stocks. Get InterCure News Delivered to You Automatically Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCR vs. The Competition Export to ExcelMetricInterCureMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.99M$10.48B$5.48B$8.94BDividend YieldN/A2.11%5.38%4.12%P/E RatioN/A17.2326.2219.74Price / Sales1.0426.99394.92109.12Price / CashN/A22.8736.4957.06Price / Book0.633.657.915.37Net Income-$18.32M$233.36M$3.15B$248.34M7 Day PerformanceN/A1.08%0.75%1.67%1 Month Performance-6.92%3.06%3.46%4.56%1 Year Performance-27.80%-11.71%34.60%18.42% InterCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCRInterCure0.8986 of 5 stars$1.48+0.7%N/A-27.1%$66.99M$64.55M0.00350ADCTADC Therapeutics1.6598 of 5 stars$2.68-3.2%$7.75+189.2%-26.6%$274.72M$75.82M-1.85310TRDAEntrada Therapeutics3.4033 of 5 stars$7.04-1.1%$25.67+264.6%-50.3%$270.23M$210.78M8.69110Trending NewsInsider TradeCRVSCorvus Pharmaceuticals2.9683 of 5 stars$3.73-5.8%$15.00+302.1%+108.6%$269.95MN/A-3.8130Positive NewsInsider TradeALLOAllogene Therapeutics3.4021 of 5 stars$1.22-0.8%$8.44+592.2%-49.4%$269.04M$20K-0.99310SGMTSagimet Biosciences2.5044 of 5 stars$8.36-4.1%$23.17+177.1%+154.1%$267.48M$2M-4.758TSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440CDTXCidara Therapeutics4.1229 of 5 stars$44.95+113.8%$45.43+1.1%+307.2%$263.73M$1.27M-1.5390Trending NewsAnalyst ForecastInsider TradeHigh Trading VolumeFHTXFoghorn Therapeutics2.1077 of 5 stars$4.89+3.6%$12.13+148.0%-16.6%$263.10M$23.50M-3.60120News CoveragePositive NewsANNXAnnexon2.8137 of 5 stars$2.38flat$12.50+425.2%-51.1%$261.12MN/A-2.0260News CoveragePositive NewsAMRNAmarin0.7374 of 5 stars$12.60+0.5%$7.00-44.4%+22.5%$259.67M$214.11M-3.46360 Related Companies and Tools Related Companies ADCT Competitors TRDA Competitors CRVS Competitors ALLO Competitors SGMT Competitors TSVT Competitors CDTX Competitors FHTX Competitors ANNX Competitors AMRN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
